Expression of vascular endothelial growth factor (VEGF) in patients with oral squamous cell carcinoma and its clinical significance

被引:42
作者
Aggarvval, Sadhna [1 ]
Devaraja, K. [2 ]
Sharma, Suresh C. [2 ]
Das, Satya N. [1 ]
机构
[1] All India Inst Med Sci, Dept Biotechnol, New Delhi 110029, India
[2] All India Inst Med Sci, Dept Otorhinolaryngol, New Delhi 110029, India
关键词
VEGF; Oral cancer; Tissue expression; Biomarker; Tumour cell proliferation; ROC analysis; PROGNOSTIC-SIGNIFICANCE; BREAST-CANCER; FACTOR FAMILY; SERUM; ANGIOGENESIS; SURVIVAL; STROMA; MODEL; GENE; HEAD;
D O I
10.1016/j.cca.2014.04.027
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
100118 [医学信息学]; 100208 [临床检验诊断学];
摘要
Background: Vascular endothelial growth factor (VEGF) is an important angiogenic cytokine that plays an important role in growth, development and progression of the tumour. We investigated expression of VEGF in oral cancer patients and its effect on proliferation of OSCC cell lines. Methods: Cell and tissue expression of VEGF was determined by qRT-PCR, western blot and immunofluorescence assay while serum level of VEGF was determined by ELISA. Tumour cell proliferation was assessed by MIT assay. Results: Serum VEGF levels were significantly higher in oral cancer patients (p < 0.0001) as compared to normal controls that further showed an increasing trend with clinical stage and lymph node involvement. In ROC analysis serum VEGF level distinguished between patients and normal subjects with a higher sensitivity (65.71%) and specificity (66.67%). It was significantly upregulated in tumour tissues and in OSCC cell lines. Exogenous VEGF treatment significantly enhanced proliferation of SCC-4 and SCC-9 cell lines. Conclusion: It seems therefore that serum VEGF level may be a reliable biomarker and may be a potential target for development of chemopreventive and chemotherapeutic strategies for patients with tobacco-related oral carcinoma. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:35 / 40
页数:6
相关论文
共 46 条
[1]
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) [J].
Achen, MG ;
Jeltsch, M ;
Kukk, E ;
Mäkinen, T ;
Vitali, A ;
Wilks, AF ;
Alitalo, K ;
Stacker, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :548-553
[2]
[Anonymous], 2008, CANC INCIDENCE MORTA
[3]
Bachelder RE, 2001, CANCER RES, V61, P5736
[4]
Brown LF, 1999, CLIN CANCER RES, V5, P1041
[5]
VEGF Exerts an Angiogenesis-Independent Function in Cancer Cells to Promote Their Malignant Progression [J].
Cao, Ying ;
E, Guangqi ;
Wang, Enfeng ;
Pal, Krishnendu ;
Dutta, Shamit K. ;
Bar-Sagi, Dafna ;
Mukhopadhyay, Debabrata .
CANCER RESEARCH, 2012, 72 (16) :3912-3918
[6]
DVORAK HF, 1995, AM J PATHOL, V146, P1029
[7]
Ferlay J, 2004, IARC CANC BASE
[8]
THE VASCULAR ENDOTHELIAL GROWTH-FACTOR FAMILY OF POLYPEPTIDES [J].
FERRARA, N ;
HOUCK, KA ;
JAKEMAN, LB ;
WINER, J ;
LEUNG, DW .
JOURNAL OF CELLULAR BIOCHEMISTRY, 1991, 47 (03) :211-218
[9]
Comparison of cancers of the oral cavity and pharynx worldwide:: etiological clues [J].
Franceschi, S ;
Bidoli, E ;
Herrero, R ;
Muñoz, N .
ORAL ONCOLOGY, 2000, 36 (01) :106-115
[10]
Friedrich RE, 2010, ANTICANCER RES, V30, P1765